Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Sophie Kubasch

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2020
Patient stratification in myelodysplastic syndromes: how a puzzle may become a mapAnne Sophie Kubasch, Uwe Platzbecker
Cancers|May 26, 2018
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AMLAnne Sophie Kubasch, Uwe Platzbecker
International Journal of Molecular Sciences|August 10, 2019
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic SyndromesAnne Sophie Kubasch, Uwe Platzbecker
Blood Advances|March 9, 2021
Development of luspatercept to treat ineffective erythropoiesisAnne Sophie Kubasch, Pierre Fenaux, Uwe Platzbecker
Frontiers in Oncology|April 18, 2022
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case SeriesAnna Stein, Anne Sophie Kubasch, Claudia Haferlach, et al.
Leukemia|May 28, 2021
Current challenges and unmet medical needs in myelodysplastic syndromesUwe Platzbecker, Anne Sophie Kubasch, Collin Homer-Bouthiette, et al.
Molecular Aspects of Medicine|July 5, 2020
Iron overload and its impact on outcome of patients with hematological diseasesGeorg-Nikolaus Franke, Anne Sophie Kubasch, Michael Cross, et al.
Neoplasia (New York, N.Y.)|October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscapeSebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancer Treatment Reviews|January 4, 2024
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomesAlmuth Maria Anni Merz, Marie Sébert, Jan Sonntag, et al.
Neuropsychiatric Disease and Treatment|June 30, 2016
Randomized controlled trials - a matter of designPeter Markus Spieth, Anne Sophie Kubasch, Ana Isabel Penzlin, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Hematology. American Society of Hematology. Education Program|December 4, 2020
Patient stratification in myelodysplastic syndromes: how a puzzle may become a mapAnne Sophie Kubasch, Uwe Platzbecker
Cancers|May 26, 2018
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AMLAnne Sophie Kubasch, Uwe Platzbecker
International Journal of Molecular Sciences|August 10, 2019
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic SyndromesAnne Sophie Kubasch, Uwe Platzbecker
Blood Advances|March 9, 2021
Development of luspatercept to treat ineffective erythropoiesisAnne Sophie Kubasch, Pierre Fenaux, Uwe Platzbecker
Frontiers in Oncology|April 18, 2022
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case SeriesAnna Stein, Anne Sophie Kubasch, Claudia Haferlach, et al.
Leukemia|May 28, 2021
Current challenges and unmet medical needs in myelodysplastic syndromesUwe Platzbecker, Anne Sophie Kubasch, Collin Homer-Bouthiette, et al.
Molecular Aspects of Medicine|July 5, 2020
Iron overload and its impact on outcome of patients with hematological diseasesGeorg-Nikolaus Franke, Anne Sophie Kubasch, Michael Cross, et al.
Neoplasia (New York, N.Y.)|October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscapeSebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancer Treatment Reviews|January 4, 2024
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomesAlmuth Maria Anni Merz, Marie Sébert, Jan Sonntag, et al.
Neuropsychiatric Disease and Treatment|June 30, 2016
Randomized controlled trials - a matter of designPeter Markus Spieth, Anne Sophie Kubasch, Ana Isabel Penzlin, et al.
Pageof 4